P&G Clears October 22 Print With Options Hedging Reversed

Procter & Gamble reports Wednesday with the put/call ratio having fallen sharply on the day, dropping to 0.679 from 0.760 the prior session, unwinding the defensive positioning that dominated the pre-print narrative.

That reversal is the sharpest single-day shift in options sentiment over the past month. The put/call ratio stood nearly two standard deviations above its 20-day average as recently as October 16, at 0.777. By October 20 it had retreated to 1.18 standard deviations below that same average, with the 20-day mean running at 0.718. The 52-week range for the ratio runs from 0.588 to 1.106, so the current reading sits near the call-heavy end of that band. Short interest offers no complication: bears hold just 1.03% of the free float, down 15% over the past month, and borrow availability is effectively unlimited. Cost to borrow is 0.41%, noise rather than signal.

The Street has been adding to the constructive side ahead of the print. Citigroup raised its target to $180 on October 14, the highest among recent movers, while RBC Capital reiterated Outperform at $166 on October 20. Evercore ISI upgraded to Outperform on October 6, lifting its target to $166. Against those, TD Cowen holds at $150 and Barclays sits at Equal-Weight with a $152 target. The mean price target across the group is $162.13, roughly 1.8% above Wednesday's close of $159.32. Forward EPS momentum ranks in the 86th percentile on a 12-month basis, though near-term estimate revisions remain softer, at the 37th to 38th percentile. The dividend score ranks in the 98th percentile, consistent with PG's defensive income profile.

The share price itself tells a clean story. PG gained 4.1% on the week to $159.32, in line with the peer median: CL added 5.1%, CHD 5.8%, and KMB led the group with a 10.2% weekly gain. WDFC was the outlier in the other direction, slipping 1.5%. The broad lift across consumer staples names makes PG's move look sector-driven rather than stock-specific, which matters for reading Wednesday's result: the macro bid that carried the group may reduce the stock's sensitivity to anything short of a significant miss.

The insider register adds a footnote worth noting. Ten directors received 1,438 shares each on October 13 as equity awards, transaction code A, compensation grants rather than open-market purchases. The 90-day net insider position is marginally negative at roughly 46,000 shares sold, so there is no discretionary buying signal to read into the board activity.

The thing to watch on October 22 is whether the organic sales growth figure for Greater China and North America aligns with the recovery narrative embedded in the $180 Citi target, or whether the bear case around SK-II weakness and soft US category growth reasserts itself against a stock that has now run 8.8% in a month.